Pharmacological Restoration of Visual Function in a Blind Zebrafish Mutant Following Histone Deacetylase Inhibitor (HDACi) Treatment
|Title:||Pharmacological Restoration of Visual Function in a Blind Zebrafish Mutant Following Histone Deacetylase Inhibitor (HDACi) Treatment||Authors:||Kennedy, Breandán
Daly, Cara T.
|Permanent link:||http://hdl.handle.net/10197/7784||Date:||Jul-2016||Online since:||2016-07-25T12:22:28Z||Abstract:||Background: Controversially, histone deacetylase (HDAC) inhibitors are in clinical trial for the treatment of inherited retinal degenerations. Previous studies report that patients suffering from Retinitis Pigmentosa (RP) show improved visual field and acuity following treatment with the HDAC inhibitor valproic acid (VPA) (Clemson, Tzekov et al. 2011). However, other studies disagree with these findings (van Schooneveld, van den Born et al. 2011) and (Bhalla, Joshi et al. 2013). Thus, we sought to determine if treatment with HDACi rescued visual function and retinal morphology in a blind zebrafish dying-on-edge (dye) mutant identified from a forward genetics screen.||Type of material:||Journal Article||Publisher:||British Pharmacological Society||Journal:||pA2 Online||Volume:||13||Issue:||3||Start page:||222P||Keywords:||Visual function; Retinal degneration; Zebrafish model||Other versions:||http://www.pa2online.org/abstracts/vol13issue3abst222p.pdf||Language:||en||Status of Item:||Not peer reviewed|
|Appears in Collections:||Conway Institute Research Collection|
Biomolecular and Biomedical Science Research Collection
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.